0001628280-21-012932.txt : 20210625 0001628280-21-012932.hdr.sgml : 20210625 20210625160325 ACCESSION NUMBER: 0001628280-21-012932 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210623 FILED AS OF DATE: 20210625 DATE AS OF CHANGE: 20210625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meisner Derek M CENTRAL INDEX KEY: 0001752461 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 211047677 MAIL ADDRESS: STREET 1: C/O GENOCEA BIOSCIENCES, INC. STREET 2: 100 ACORN PARK DRIVE, 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wf-form4_162465138910056.xml FORM 4 X0306 4 2021-06-23 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001752461 Meisner Derek M C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134 0 1 0 0 General Counsel Common Stock 2021-06-23 4 A 0 12500 0 A 85228 D Common Stock 2021-06-24 4 S 0 4166 7 D 81062 D Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.86 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents unvested restricted stock units. /s/ Derek M. Meisner 2021-06-25